{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:33:25Z","timestamp":1783488805489,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T00:00:00Z","timestamp":1524441600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s40273-018-0656-z","type":"journal-article","created":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T01:24:39Z","timestamp":1524446679000},"page":"1005-1013","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors"],"prefix":"10.1007","volume":"36","author":[{"given":"Chan","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Dasari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyi","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouhao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Chen Tina","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,23]]},"reference":[{"key":"656_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.6004\/jnccn.2015.0011","volume":"13","author":"MH Kulke","year":"2015","unstructured":"Kulke MH, Shah MH, Benson AB 3rd, et al. Neuroendocrine tumors, version 1.2015. J Natl Compr Cancer Netw. 2015;13:78\u2013108.","journal-title":"J Natl Compr Cancer Netw"},{"key":"656_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1200\/JCO.2016.70.7364","volume":"35","author":"DM Halperin","year":"2017","unstructured":"Halperin DM, Yao JC, Dasari A. What\u2019s in a name? Steady progress in staging pancreatic neuroendocrine tumors. J Clin Oncol. 2017;35:265\u20137.","journal-title":"J Clin Oncol"},{"key":"656_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nature21063","volume":"543","author":"A Scarpa","year":"2017","unstructured":"Scarpa A, Chang DK, Nones K, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543:65\u201371.","journal-title":"Nature"},{"key":"656_CR4","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1038\/ng.2821","volume":"45","author":"JM Francis","year":"2013","unstructured":"Francis JM, Kiezun A, Ramos AH, et al. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet. 2013;45:1483\u20136.","journal-title":"Nat Genet"},{"key":"656_CR5","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, et al. One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063\u201372.","journal-title":"J Clin Oncol"},{"issue":"10","key":"656_CR6","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335\u201342.","journal-title":"JAMA Oncol."},{"key":"656_CR7","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1001\/jamaoncol.2017.0575","volume":"3","author":"PL Kunz","year":"2017","unstructured":"Kunz PL. Understanding neuroendocrine tumors\u2014a NET gain. JAMA Oncol. 2017;3:1343\u20134.","journal-title":"JAMA Oncol"},{"key":"656_CR8","unstructured":"Cubanski J, et al. How much is enough? Out-of-pocket spending among Medicare beneficiaries: a chartbook. 2014. \n                    http:\/\/kff.org\/report-section\/how-much-is-enough-out-of-pocket-spending-among-medicare-beneficiariessection-1\n                    \n                  . Accessed 16 Apr 2018."},{"key":"656_CR9","unstructured":"American Cancer Society. The costs of cancer addressing patient costs. \n                    https:\/\/www.acscan.org\/sites\/default\/files\/Costs%20of%20Cancer%20-%20Final%20Web.pdf\n                    \n                  . Accessed 1 Oct 2017."},{"key":"656_CR10","unstructured":"Agency for Healthcare Research and Quality. Total expenses and percent distribution selected conditions by source of payment: United States, 2014. \n                    https:\/\/meps.ahrq.gov\/data_stats\/tables_compendia_hh_interactive.jsp?_SERVICE=MEPSSocket0&_PROGRAM=MEPSPGM.TC.SAS&File=HCFY2014&Table=HCFY2014_CNDXP_D&_Debug\n                    \n                  . Accessed 1 Oct 2017."},{"key":"656_CR11","unstructured":"National Cancer Institute. Surveillance, epidemiology, and end results program. \n                    https:\/\/seer.cancer.gov\/\n                    \n                  . Accessed 1 Nov 2017."},{"key":"656_CR12","first-page":"Iv-3-18","volume":"40","author":"JL Warren","year":"2002","unstructured":"Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40:Iv-3-18.","journal-title":"Med Care."},{"key":"656_CR13","unstructured":"National Cancer Institute. Cancer prevalence and cost of care projections. \n                    https:\/\/costprojections.cancer.gov\/\n                    \n                  . Accessed 1 Oct 2017."},{"key":"656_CR14","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1093\/jnci\/djn103","volume":"100","author":"KR Yabroff","year":"2008","unstructured":"Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008;100:630\u201341.","journal-title":"J Natl Cancer Inst"},{"key":"656_CR15","unstructured":"Bureau of Labor Statistics. \n                    http:\/\/www.bls.gov\/data\/\n                    \n                  . Accessed 1 Oct 2017."},{"key":"656_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/jnci\/djq495","volume":"103","author":"AB Mariotto","year":"2011","unstructured":"Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103:117\u201328.","journal-title":"J Natl Cancer Inst"},{"key":"656_CR17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","volume":"18","author":"DM Halperin","year":"2017","unstructured":"Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18:525\u201334.","journal-title":"Lancet Oncol"},{"key":"656_CR18","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656\u201363.","journal-title":"J Clin Oncol"},{"key":"656_CR19","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501\u201313.","journal-title":"N Engl J Med"},{"key":"656_CR20","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514\u201323.","journal-title":"N Engl J Med"},{"key":"656_CR21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1055\/s-0037-1602590","volume":"34","author":"RC Gaba","year":"2017","unstructured":"Gaba RC, Mendoza-Elias N, Morrison JD, Valeshabad AK, Lipnik AJ. Decision making for selection of transarterial locoregional therapy of metastatic neuroendocrine tumors. Semin Intervent Radiol. 2017;34:101\u20138.","journal-title":"Semin Intervent Radiol"},{"issue":"11","key":"656_CR22","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1245\/s10434-017-5986-0","volume":"24","author":"J Hallet","year":"2017","unstructured":"Hallet J, Law CHL, Cheung M, et al. Patterns and drivers of costs for neuroendocrine tumor care: a comparative population-based analysis. Ann Surg Oncol. 2017;24(11):3312\u201323.","journal-title":"Ann Surg Oncol."},{"key":"656_CR23","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.cgh.2008.08.034","volume":"7","author":"K Lang","year":"2009","unstructured":"Lang K, Lines LM, Lee DW, Korn JR, Earle CC, Menzin J. Lifetime and treatment-phase costs associated with colorectal cancer: evidence from SEER-Medicare data. Clin Gastroenterol Hepatol. 2009;7:198\u2013204.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"656_CR24","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1158\/1055-9965.EPI-11-0650","volume":"20","author":"KR Yabroff","year":"2011","unstructured":"Yabroff KR, Lund J, Kepka D, Mariotto A. Economic burden of cancer in the US: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev. 2011;20:2006\u201314.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"656_CR25","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10549-017-4249-x","volume":"164","author":"BT Allaire","year":"2017","unstructured":"Allaire BT, Ekwueme DU, Poehler D, et al. Breast cancer treatment costs in younger, privately insured women. Breast Cancer Res Treat. 2017;164:429\u201336.","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"656_CR26","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1634\/theoncologist.2017-0149","volume":"22","author":"C Shen","year":"2017","unstructured":"Shen C, Chu Y, Halperin DM, et al. Carcinoid syndrome and costs of care during the first year after diagnosis of neuroendocrine tumors among elderly patients. Oncologist. 2017;22(12):1451\u201362.","journal-title":"Oncologist."},{"key":"656_CR27","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1093\/jnci\/djn384","volume":"100","author":"CJ Bradley","year":"2008","unstructured":"Bradley CJ, Yabroff KR, Dahman B, Feuer EJ, Mariotto A, Brown ML. Productivity costs of cancer mortality in the United States: 2000\u20132020. J Natl Cancer Inst. 2008;100:1763\u201370.","journal-title":"J Natl Cancer Inst"},{"key":"656_CR28","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1097\/MLR.0000000000000151","volume":"52","author":"KR Yabroff","year":"2014","unstructured":"Yabroff KR, Guy GP, Ekwueme DU, et al. Annual patient time costs associated with medical care among cancer survivors in the United States. Med Care. 2014;52:594\u2013601.","journal-title":"Med Care"},{"issue":"5","key":"656_CR29","doi-asserted-by":"publisher","first-page":"djv382","DOI":"10.1093\/jnci\/djv382","volume":"108","author":"Z Zheng","year":"2015","unstructured":"Zheng Z, Yabroff KR, Guy GP, et al. Annual medical expenditure and productivity loss among colorectal, female breast, and prostate cancer survivors in the United States. J Natl Cancer Inst. 2015;108(5):djv382.","journal-title":"J Natl Cancer Inst."},{"issue":"5","key":"656_CR30","doi-asserted-by":"publisher","first-page":"djv370","DOI":"10.1093\/jnci\/djv370","volume":"108","author":"SY Zafar","year":"2016","unstructured":"Zafar SY. Financial toxicity of cancer care: it\u2019s time to intervene. J Natl Cancer Inst. 2016;108(5):djv370.","journal-title":"J Natl Cancer Inst."},{"key":"656_CR31","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.4158\/EP151172.OR","volume":"22","author":"AI Vinik","year":"2016","unstructured":"Vinik AI, Wolin EM, Liyanage N, Gomez-Panzani E, Fisher GA. Evaluation of lanreotide depot\/autogel efficacy and safety as a carcinoid syndrome treatment (ELECT): a randomized, double-blind, placebo-controlled trial. Endocr Pract. 2016;22:1068\u201380.","journal-title":"Endocr Pract"},{"key":"656_CR32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125\u201335.","journal-title":"N Engl J Med"},{"key":"656_CR33","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387:968\u201377.","journal-title":"Lancet"},{"key":"656_CR34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","volume":"35","author":"MH Kulke","year":"2017","unstructured":"Kulke MH, Horsch D, Caplin ME, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol. 2017;35:14\u201323.","journal-title":"J Clin Oncol"},{"key":"656_CR35","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224\u201333.","journal-title":"N Engl J Med"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-018-0656-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0656-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0656-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T09:43:05Z","timestamp":1589881385000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-018-0656-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,23]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["656"],"URL":"https:\/\/doi.org\/10.1007\/s40273-018-0656-z","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,23]]},"assertion":[{"value":"23 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was supported in part by Ipsen. The funder sponsored the purchase of SEER-Medicare data and provided funding for analytical support.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Chan Shen, Arvind Dasari, Dian Gu, Yiyi Chu, Shouhao Zhou, Ying Xu, Daniel Halperin, Shuangshuang Fu, and Ya-Chen Tina Shih declare they have no financial or non-financial conflicts of interest that are directly relevant to the content of this article. James C. Yao declares consulting fees or honorarium from Novartis and Ipsen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data source used for this study is SEER registry data linked with Medicare claims. It is available upon request from the SEER-Medicare program.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}}]}}